Business
Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2026 List of America's Most Successful Small-Cap Companies
CORAL GABLES, Fla., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced its inclusion in Forbes' esteemed list of America's Most Successful Small-Cap Companies for the year 2026. Catalyst has ranked an impressive 11 out of 100 companies on the list
About this update from Catalyst Pharmaceuticals, Inc.
[{"type":"image","alt":"Catalyst Pharmaceuticals, Inc.","displaySize":"","headline":null,"caption":"Catalyst Pharmaceuticals, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":291,"height":95,"url":"https://media.zenfs.com/en/globenewswire.com/acd4b49518224322238ae470f071342d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/D7rqLycsFEMrXMBp0B5H3Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzNztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/acd4b49518224322238ae470f071342d","width":291,"height":95}},"lazy":false},{"type":"text","content":"CORAL GABLES, Fla., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced its inclusion in Forbes' esteemed list of America's Most Successful Small-Cap Companies for the year 2026. Catalyst has ranked an impressive 11 out of 100 companies on the list.","length":529,"tagName":"p"},{"type":"text","content":"“We are honored to once again be recognized on Forbes’ list of America’s Most Successful Small-Cap Companies for 2026,” said Rich Daly, President and CEO, Catalyst. “Our accomplishments over the past year reflect the unwavering dedication of all our employees and our unwavering commitment to the rare disease patient communities we serve.”","length":340,"tagName":"p"},{"type":"text","content":"To compile the list, Forbes used data from FactSet to find 621 companies with a market value between $300 million and $5 billion that also had positive sales growth over the past 12 months and a share price of at least $5. Financial institutions, REITs, utilities, royalty trusts and limited partnerships were excluded, as were companies that have been public for less than one year. The top 100 stocks were ranked based on earnings growth, sales growth, return on equity and total stock return for the last five years available, with more weight given to the last 12 months of data. All data is as of October 31, 2025.","length":619,"tagName":"p"},{"type":"text","content":"About Catalyst Pharmaceuticals, Inc.Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX), is a biopharmaceutical company committed to improving the lives of patients with ...